Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease

被引:3
|
作者
Baldaranov, Dobri [1 ]
Garcia, Victoria [1 ]
Miller, Garrett [1 ]
Donohue, Michael C. [1 ]
Shaw, Leslie M. [2 ]
Weiner, Mike [3 ,4 ,5 ,6 ,7 ]
Petersen, Ronald C. [8 ]
Aisen, Paul [1 ]
Raman, Rema [1 ]
Rafii, Michael S. [1 ]
机构
[1] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego 9860 Mesa Rim Rd, San Diego, CA 92121 USA
[2] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA
[3] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[8] Mayo Clin, Dept Neurol, Mayo Clin Study Aging, Mayo Clin Neurol & Neurosurg,Alzheimers Dis Res Ct, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
adverse effects; Alzheimer's disease; biomarker; brain volume; cerebrospinal fluid; lumbar puncture; pain relief medication; MULTICENTER; BIOMARKERS;
D O I
10.1002/dad2.12431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionLumbar puncture (LP) to collect and examine cerebrospinal fluid (CSF) is an important option for the evaluation of Alzheimer's disease (AD) biomarkers but it is not routinely performed due to its invasiveness and link to adverse effects (AE). MethodsWe include all participants who received at least one LP in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study. For comparison between groups, two-sample t-tests for continuous, and Pearson's chi-square test for categorical variables were performed. ResultsTwo hundred twenty-seven LP-related AEs were reported by 172 participants after 1702 LPs (13.3%). The mean age of participants who reported at least one AE was 69.79 (standard deviation (SD) 6.3) versus none 72.44 (7.17) years (p < 0.001) with female predominance (115/172 = 67.4% vs 435/913 = 48%), and had greater entorhinal cortical thickness and hippocampal volume (3.903 (0.782) vs 3.684 (0.775) mm, p = 0.002; 7.38 (1.06) vs 7.05 (1.15) mm(3), p < 0.001), respectively. DiscussionWe found that younger age, female sex, and greater thickness of the entorhinal cortex were associated with a higher rate of LP-related AE reports.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability
    Thussu, Shreeya
    Naidu, Aniketh
    Manivannan, Sindhu
    Grossberg, George T.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (11) : 1045 - 1053
  • [22] Update: Alzheimer's Disease
    Reich, A.
    Schulz, J. B.
    AKTUELLE NEUROLOGIE, 2011, 38 (05) : 234 - 241
  • [23] Safety and acceptability of the research lumbar puncture
    Peskind, ER
    Riekse, R
    Quinn, JF
    Kaye, J
    Clark, CM
    Farlow, MR
    DeCarli, C
    Chabal, C
    Vavrek, D
    Raskind, MA
    Galasko, D
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2005, 19 (04): : 220 - 225
  • [24] Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer's disease
    Hajos, Mihaly
    Boasso, Alyssa
    Hempel, Evan
    Shpokayte, Monika
    Konisky, Alex
    Seshagiri, Chandran V.
    Fomenko, Vitella
    Kwan, Kim
    Nicodemus-Johnson, Jessie
    Hendrix, Suzanne
    Vaughan, Brent
    Kern, Ralph
    Megerian, Jonathan T.
    Malchano, Zach
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [25] Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia
    Hannestad, Jonas
    Koborsi, Katie
    Klutzaritz, Vicki
    Chao, Whitney
    Ray, Rebecca
    Paez, Antonio
    Jackson, Sam
    Lohr, Scott
    Cummings, Jeffrey L.
    Kay, Gary
    Nikolich, Karoly
    Braithwaite, Steven
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2020, 6 (01)
  • [26] Safety and tolerability of metrifonate in patients with Alzheimer's disease: Results of a maximum tolerated dose study
    Cutler, NR
    Jhee, SS
    Cyrus, P
    Bieber, F
    TanPiengco, P
    Sramek, JJ
    Gulanski, B
    LIFE SCIENCES, 1998, 62 (16) : 1433 - 1441
  • [27] Quantitative evaluation of Alzheimer's disease
    Duchesne, S.
    Frisoni, G. B.
    MEDICAL IMAGING 2009: COMPUTER-AIDED DIAGNOSIS, 2009, 7260
  • [28] Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer's Disease Dementia
    Hsieh, Sun-Wung
    Chen, Jui-Cheng
    Chen, Nai-Ching
    Jhang, Kai-Ming
    Wang, Wenfu
    Yang, Yuan-Han
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021, 19 (03) : 447 - 457
  • [29] A feasibility and tolerability study of lithium in Alzheimer's disease
    Macdonald, Alastair
    Briggs, Kate
    Poppe, Michaela
    Higgins, Andrea
    Velayudhan, Latha
    Lovestone, Simon
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (07) : 704 - 711
  • [30] A Disease State Fingerprint for Evaluation of Alzheimer's Disease
    Mattila, Jussi
    Koikkalainen, Juha
    Virkki, Arho
    Simonsen, Anja
    van Gils, Mark
    Waldemar, Gunhild
    Soininen, Hilkka
    Lotjonen, Jyrki
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 27 (01) : 163 - 176